Soleno Therapeutics (SLNO) Competitors $67.67 -0.74 (-1.08%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$67.19 -0.48 (-0.71%) As of 08/29/2025 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SLNO vs. FEMY, IMVT, SOLV, PEN, STVN, IRTC, GKOS, BLCO, TMDX, and NVSTShould you be buying Soleno Therapeutics stock or one of its competitors? The main competitors of Soleno Therapeutics include Femasys (FEMY), Immunovant (IMVT), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), iRhythm Technologies (IRTC), Glaukos (GKOS), Bausch + Lomb (BLCO), TransMedics Group (TMDX), and Envista (NVST). These companies are all part of the "medical" sector. Soleno Therapeutics vs. Its Competitors Femasys Immunovant Solventum Penumbra Stevanato Group iRhythm Technologies Glaukos Bausch + Lomb TransMedics Group Envista Femasys (NASDAQ:FEMY) and Soleno Therapeutics (NASDAQ:SLNO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment. Which has better earnings & valuation, FEMY or SLNO? Femasys has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFemasys$1.63M7.10-$18.82M-$0.86-0.41Soleno TherapeuticsN/AN/A-$175.85M-$4.14-16.35 Which has more risk and volatility, FEMY or SLNO? Femasys has a beta of -2.63, meaning that its stock price is 363% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -2.71, meaning that its stock price is 371% less volatile than the S&P 500. Does the media prefer FEMY or SLNO? In the previous week, Soleno Therapeutics had 18 more articles in the media than Femasys. MarketBeat recorded 23 mentions for Soleno Therapeutics and 5 mentions for Femasys. Soleno Therapeutics' average media sentiment score of 1.04 beat Femasys' score of 0.40 indicating that Soleno Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Femasys 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Soleno Therapeutics 13 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in FEMY or SLNO? 65.3% of Femasys shares are held by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are held by institutional investors. 11.5% of Femasys shares are held by insiders. Comparatively, 6.4% of Soleno Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is FEMY or SLNO more profitable? Soleno Therapeutics has a net margin of 0.00% compared to Femasys' net margin of -1,113.72%. Soleno Therapeutics' return on equity of -73.74% beat Femasys' return on equity.Company Net Margins Return on Equity Return on Assets Femasys-1,113.72% -713.74% -152.60% Soleno Therapeutics N/A -73.74%-56.67% Do analysts recommend FEMY or SLNO? Femasys currently has a consensus price target of $7.33, suggesting a potential upside of 1,965.15%. Soleno Therapeutics has a consensus price target of $115.09, suggesting a potential upside of 70.08%. Given Femasys' higher possible upside, equities research analysts clearly believe Femasys is more favorable than Soleno Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08 SummarySoleno Therapeutics beats Femasys on 9 of the 16 factors compared between the two stocks. Get Soleno Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLNO vs. The Competition Export to ExcelMetricSoleno TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.60B$2.51B$5.71B$9.76BDividend YieldN/A48.51%6.66%4.48%P/E Ratio-16.3522.6183.1026.57Price / SalesN/A731.65544.91112.35Price / CashN/A26.3325.6628.92Price / Book11.915.3711.766.08Net Income-$175.85M$32.95M$3.27B$265.84M7 Day Performance1.74%-0.65%1.13%0.36%1 Month Performance-21.31%6.46%8.30%5.58%1 Year Performance38.24%-3.15%62.26%19.67% Soleno Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLNOSoleno Therapeutics4.4991 of 5 stars$67.67-1.1%$115.09+70.1%+38.2%$3.60BN/A-16.3530Positive NewsFEMYFemasys3 of 5 stars$0.52-9.8%$7.33+1,323.7%-69.6%$18.60M$1.63M0.0030Gap UpHigh Trading VolumeIMVTImmunovant2.8922 of 5 stars$14.89-2.3%$35.20+136.4%-52.5%$2.66BN/A0.00120Positive NewsSOLVSolventum2.3305 of 5 stars$72.82-1.0%$85.75+17.8%+14.1%$12.75B$8.25B13.1622,000Positive NewsAnalyst UpgradePENPenumbra4.8927 of 5 stars$265.19+0.2%$300.47+13.3%+34.9%$10.32B$1.19B70.534,500Positive NewsAnalyst UpgradeSTVNStevanato GroupN/A€21.99-2.8%N/A+5.8%€6.66B€1.19B40.725,521Positive NewsIRTCiRhythm Technologies1.3935 of 5 stars$165.68-2.0%$162.64-1.8%+139.8%$5.43B$591.84M-56.552,000Positive NewsGKOSGlaukos4.7615 of 5 stars$91.78-2.5%$127.42+38.8%-28.4%$5.40B$383.48M-55.62780News CoveragePositive NewsBLCOBausch + Lomb1.7584 of 5 stars$14.57-2.5%$15.56+6.8%-10.9%$5.29B$4.79B35.5713,500TMDXTransMedics Group3.1093 of 5 stars$114.97-4.1%$123.00+7.0%-31.6%$4.09B$441.54M62.10210News CoverageAnalyst DowngradeNVSTEnvista4.0494 of 5 stars$21.15-2.6%$20.92-1.1%+15.8%$3.61B$2.51B25.2612,300News CoveragePositive NewsAnalyst Downgrade Related Companies and Tools Related Companies Femasys Alternatives Immunovant Alternatives Solventum Alternatives Penumbra Alternatives Stevanato Group Alternatives iRhythm Technologies Alternatives Glaukos Alternatives Bausch + Lomb Alternatives TransMedics Group Alternatives Envista Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLNO) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersNew Banking Law #1582 Could Unlock $21 Trillion for AmericansDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SLNO Stock Alerts